Researcher
Nathan De Beule
- Keywords:Medicine
- Disciplines:Other translational sciences not elsewhere classified, Other basic sciences not elsewhere classified, Human and medical genetics not elsewhere classified, Other clinical sciences not elsewhere classified
Affiliations
- Hematology (Department)
Member
From1 Aug 2018 → Today - Hematology (Research group)
Member
From1 Oct 2012 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Clinical sciences (Department)
Member
From1 Feb 2021 → 4 Dec 2021 - Internal medicine (Department)
Member
From1 Aug 2018 → 9 Sep 2018 - Faculty of Medicine and Pharmacy (Faculty)
Member
From9 Sep 2016 → 27 Jun 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From17 Sep 2015 → 24 Apr 2018 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2016 - Immunology and Microbiology (Department)
Member
From1 Oct 2012 → 31 Dec 2013 - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Jul 2012 → 13 Oct 2015 - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Sep 2008 → 29 Jun 2012
Publications
1 - 10 of 11
- Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma(2023)
Authors: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, et al.
- Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism(2023)
Authors: Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M Knight, Nathan De Beule, Gamze Ates, Ann Massie, et al.
Pages: 69–80 - The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers(2022)
Authors: Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
- Dendritische cellen als immunotherapie voor multipel myeloom(2022)
Authors: Emma Verheye, Nathan De Beule, Damya Laoui, Kim De Veirman
Pages: 35-38 - AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies(2019)
Authors: Siyang Yan, Niels Vandewalle, Nathan De Beule, Sylvia Faict, Ken Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Kim De Veirman
Pages: 1-17 - Correction(2018)
Authors: Nathan De Beule, Eline Menu, Mathieu J. M. Bertrand, Mérédis Favreau, Elke De Bruyne, Ken Maes, Kim De Veirman, Magdalena Radwanska, Afshin Samali, Stefan Magez, et al.
Pages: 22871-22871 - Extracellular S100A9 protein in bone marrow supports multiple myeloma survival by stimulating angiogenesis and cytokine secretion(2017)
Authors: Kim De Veirman, Nathan De Beule, Ken Maes, Eline Menu, Elke De Bruyne, Hendrik De Raeve, Karel Fostier, Jerome Moreaux, Alboukadel Kassambara, Dirk Hose, et al.
Pages: 839-846 - Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation(2017)
Authors: Nathan De Beule, Kim De Veirman, Ken Maes, Elke De Bruyne, Eline Menu, Karine Breckpot, Hendrik De Raeve, Rian Van Rampelbergh, Jo A Van Ginderachter, Rik Schots, et al.
Pages: 534-546 - Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells(2017)
Authors: Nathan De Beule, Eline Menu, Mathieu Jm Bertrand, Mérédis Favreau, Elke De Bruyne, Ken Maes, Kim De Veirman, Magdalena Radwanska, Afshin Samali, Stefan Magez, et al.
Pages: 534-546 - The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells(2015)
Authors: Jinheng Wang, Kim De Veirman, Nathan De Beule, Ken Maes, Elke De Bruyne, E Van Valckenborgh, Karin Vanderkerken, Eline Menu
Pages: 43992-44004